Infectious Disease

COVID-19

Questions discussed in this category

What is your approach to the use of Paxlovid for patients with risk factors for severe Covid-19 infection but who have received SARS-CoV-2 vaccines in light of the EPIC-SR trial findings?

EPIC-SR Trial

2 Answers available

What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?

CDC Healthcare Guidance CDC Isolation and Work Restriction Guidance CDC Immunocompromised Guidance

1 Answer available

In a patient who is on oral DMARDs and has received 3 COVID boosters, but recently had COVID-19 infection, is bivalent booster still recommended 3 months later?

4 Answers available

How do you approach the timing of COVID-19 vaccination for patients with multiple sclerosis on B-cell depleting therapies?

3 Answers available

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

1 Answer available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?

2 Answers available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

Papers discussed in this category

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Neurology, 2020 Jul 29

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.

Cells, 2018 Dec 28

Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.

Ann Oncol, 2021 Mar 18

Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.

The New England journal of medicine, 2024 Apr 04

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.

Related Topics in Infectious Disease